We studied the DNA isolated from 20 Italian males carryinf haemophilia B using a cDNA probe for factor IX. A large gene deletion was detected in one subject, while the DNA patterns of the other haemophilia B patients were indistinguishable from normal.
Thyroglobulin genomic probe was a generous gift from Dr E Avvedimento.
Hybridisation was performed in accordance with the Gene Screen transfer membrane method (New England Nuclear, Boston). Excess probe was washed off by incubation with 0-06 mol/l Tris-HCl (pH 8), 0-3 mol/l NaCl, 0-002 molI EDTA, and 1% SDS at 60°C for one hour, followed by incubation in 0*03 mol/l NaCl, 0-006 mol/l Tris (pH 8), and 0-0002 mol/l EDTA for one hour at room temperature.
Results
The DNA from the 20 haemophilia B subjects under study were digested with EcoRI restriction enzyme and after Southern blotting hybridised to a factor IX cDNA probe (for which we thank Dr G G Brownlee). The DNA of case 1 was analysed further using XbaI, TaqI, HindlIl, and BamHI restriction enzymes and the same cDNA probe. The results obtained (fig 2a) confirm that the DNA of this patient fails to hybridise with factor IX probe.
In order to assess the presence of hybridisable DNA in the Southern blots of case 1, the EcoRI digest was additionally tested with a thyroglobulin gene probe (fig 2b) . Like the normal control, patient 1 showed the thyroglobulin specific 2 kb band. The DNA of case 1 also gave normal results when hybridised with a y globin gene probe (data not presented).
Discussion
The DNA of an Italian subject carrying haemophilia B, digested with several restriction enzymes, did not show hybridisation fragments when tested with a factor IX cDNA probe. As the cDNA used hybridises to all factor IX exons, the findings obtained indicate that the DNA coding regions were deleted and, since the gene for factor IX is 34 kb in length,8 this is the smallest extent of the deletion, provided that more complex rearrangements are not present.
Large and heterogeneous structural changes in the factor IX gene have already been described by Giannelli et al 9 and Peake et all' in the United Kingdom. Neither in the British patients so far described nor in this Italian patient are the end points of the DNA lesion known. DNA sequences 3' and 5' to the factor IX gene will be needed to determine the precise extent of the lesion, which, as in thalassaemia,'-3 could be very extensive and generated through a similar molecular mech- 13 14 anism.
Taken together, previous published reports and the present data indicate that the majority of the gene defects causing haemophilia B are due to small deletions or point mutations, impairing gene expression or the structure-function relationship of the molecule, as in haemophilia B Chapel Hill. '
As in the British patients, our patient has antibodies to the factor IX concentrate administered for therapeutic purposes. The other 19 haemophilia B patients considered, whose hybridisation pattern with factor IX cDNA probe was normal, do not produce antibodies to the infused factor IX. These data support the hypothesis of Giannelli et al 9 that patients with a gross gene defect, leading to the absence of immunologically recognisable factor IX, develop antibodies to the factor, which make its infusion inefficient.
We thank Dr G G Brownlee for the factor IX cDNA probe, Dr E Avvedimento for the thyroglobulin genomic probe, and E Mariotti and V Margutti for preparing the manuscript. haemophilia B subject. 
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